Free to Breathe is pleased to announce that Neal Meropol, MD, FASCO, is the winner of the first Accelerate Clinical Trials (ACT) Research Grant award. ACT is a new grant funding opportunity launched by Free to Breathe to investigate strategies or interventions to increase patient enrollment in therapeutic lung cancer clinical trials. Dr. Meropol’s winning grant was selected by a panel of expert researchers and physicians.
The intent of the Free to Breathe ACT Research Grant is to fund projects that will be reproducible and implementable within clinical practice. An overall goal is to improve rates of patient accrual to lung cancer clinical trials by at least 50% within a defined healthcare facility, system or community. In 2016, Free to Breathe expects to support up to three additional ACT grant awards of $100,000 each to be paid over 2 years. The winner(s) will be announced in late 2016.
For questions about the Research Grant competition, please contact:
Mary F. Henningfield, PhD
During the grant period, Trial Prospector will be enhanced and customized to match lung cancer patients with available clinical trials. Once the enhancements are completed, Trial Prospector will be tested in lung cancer clinics to help validate that its use can be incorporated into routine clinical practice. Once optimized, Trial Prospector will automatically review medical data and match clinical characteristics against a database of clinical trial eligibility criteria, all before the scheduled office visit. Having a list of potential studies readily available would allow physicians and patients to discuss clinical trial options during the patient’s office visit.
By creating a point-of-care tool that is accurate, timesaving and appealing to oncologists, Dr. Meropol and his colleagues strive to double patient accrual to lung cancer clinical trials in thoracic oncology clinics at the Seidman Cancer Center of the Case Western Reserve University Comprehensive Cancer Center. The research results will be used to prepare Trial Prospector for widespread dissemination and incorporation into clinical practice for all cancer patients.
©2017 Free To Breathe | All rights reserved. | Federal tax exempt ID number: 45-0505050.